Pharmacological activation of REV-ERBα by SR9009 attenuated hepatic steatosis, insulin resistance, inflammation, and fibrosis in mice with intestinal barrier dysfunction-related disorders and NASH [233]. The gene discussed is NR1D1; the disease is Hepatic steatosis.